Shots:

• The collaboration allows MD Anderson to conduct multiple clinical studies for multiple rare cancer indications. MD Anderson plans to develop an approach- upon commercialization in rare diseases and will receive royalties on sales of the product in the US- used it to fund for uninsured patients
• The focus of the collaboration is to advance sintilimab as an effective immune checkpoint inhibitor for patients with rare cancer types. Innovent and MD Anderson will co-fund the development activities for sintilimab- which may include multiple clinical research studies to be conducted by MD Anderson
• The collaboration provides Innovent an opportunity to pursue the US FDA’s approval of sintilimab for multiple rare cancer indications in addition to larger cancer indications that Innovent is independently pursuing for approval as well

Click here ­to­ read full press release/ article 

Ref: PRNewswire | Image: Innovent